Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Acclaimed clinical researcher, Professor Laurent Servais, has been appointed Professor of Paediatric Neuromuscular Diseases at the MDUK Oxford Neuromuscular Centre. The centre is a partnership between Muscular Dystrophy UK (MDUK) and the University of Oxford with the aim of driving research into potential treatments from the lab into the clinic.

Professor Servais will join the MDUK Oxford Neuromuscular Centre with a wealth of experience within the neuromuscular field. He has overseen numerous clinical trials to test treatments for Duchenne muscular dystrophy and spinal muscular atrophy (SMA). He is also the leader of the newborn screening program for SMA in southern Belgium. His main research expertise covers the development of innovative outcome measures, including connected devices for real-life patients’ evaluation.

Professor Servais is currently Head of the Institute I-Motion, in Paris, and Head of the Neuromuscular Centre in Liège, Belgium. He is also a Professor of Child Neurology at Liège University. He will cease his activity in Paris, but will keep an affiliation in his hometown hospital and university as an invited Professor.  Professor Servais will start his tenure with the MDUK Oxford Neuromuscular Centre in September 2019 and will relocate to Oxford from Belgium.

Commenting on his appointment, Professor Servais, said:

I’m really pleased to be joining the MDUK Oxford Neuromuscular Centre. It is an exciting time for research as we build our understanding of muscle-wasting conditions and more potential treatments are discovered. I look forward to joining the buoyant department of paediatrics and this team of brilliant and committed scientists, project managers and physicians, and bringing my experience of clinical trial development to the centre to help accelerate the process of bringing new treatments to patients.I am very excited by the challenge to develop a team in such a stimulating human and scientific environment. I also truly believe that there is a high potential synergy between the Centres of Liège and Oxford, and that both sites may benefit from a close collaboration.

Professor Matthew Wood, Director of the MDUK Oxford Neuromuscular Centre and Professor of Neuroscience at the University of Oxford, said:

Laurent’s appointment is a real coup for the centre. With emerging treatments for muscle-wasting conditions on the horizon, the need and demand for clinical trials is greater than ever, but we know that a lack of staff and expertise can lead to fewer trials taking place. Laurent’s experience, particularly of designing and leading innovative clinical trials for Duchenne and SMA, will be invaluable if we are to lead the way in improving how clinical trials are managed and run. Only by doing this can we achieve our urgent goal of bringing new treatments to patients more quickly.

The MDUK Oxford Neuromuscular Centre is housed by the University of Oxford’s Department of Paediatrics and was established in January 2019. It aims to speed up the process of translating scientific research into clinical trials and to improve infrastructure of such trials to make sure more of these take place more cost-effectively. This will in turn help people with muscle-wasting conditions access effective new treatments more quickly than ever before.

Similar stories

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

National consortium to study threats of new SARS-CoV-2 variants

Coronavirus COVID-19 General Research

A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).

Retirement of Professor Peter Brown

General

This month sees the retirement of Professor Peter Brown as Director of the Medical Research Council Brain Network Dynamics Unit at the University of Oxford.

Immunology preprint reviews launched in Nature Reviews Immunology

General Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

General Research

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

General Research

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.